{"schema_version":"secwatch.filing_event.v1","accession":"0001933414-24-000038","form_type":"8-K","ticker":"MLYS","cik":"0001933414","company_name":"Mineralys Therapeutics, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.221790+00:00","generated_at":"2026-05-31T09:51:40.128163+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Mineralys reports Q2 net loss $41M; Advance-HTN trial ~90% enrolled, on track for Q1 2025 data","bullets":["Net loss of $41.0M for Q2 2024 vs $12.1M in Q2 2023; cash and investments of $311.1M as of June 30, 2024.","Advance-HTN pivotal trial ~90% enrolled; topline data expected Q1 2025 after FDA alignment on primary endpoint.","Launch-HTN Phase 3 enrollment ahead of schedule; topline data on track for 2H 2025.","Explore-CKD Phase 2 trial enrollment ramping; topline data expected 1H 2025.","Cash runway into 2026 covers planned clinical studies and corporate operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001933414-24-000038","json":"https://secwatch.observer/filing/0001933414-24-000038.json","markdown":"https://secwatch.observer/filing/0001933414-24-000038.md","text":"https://secwatch.observer/filing/0001933414-24-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933414/000193341424000038/0001933414-24-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933414/000193341424000038/mlys-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:51:40.128163+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}